Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XSpray Pharma ABOSTO:XSPRAY +1.44%29 Buyback Yield % is -22.26 as of Aug. 03, 2026. GuruFocus rates OSTO:XSPRAY with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 735 Biotechnology companies, XSpray Pharma AB ranks worse than 68.3% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for XSpray Pharma AB's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:XSPRAY vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, XSpray Pharma AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XSpray Pharma AB Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where XSpray Pharma AB's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSpray Pharma AB (OSTO:XSPRAY) has a Buyback Yield % of -22.26 as of Aug. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on XSpray Pharma AB and its competitors. According to the industry distribution chart, XSpray Pharma AB ranks #502 out of 735 companies in the Biotechnology industry, placing it in the top 68.3%.
Is XSpray Pharma AB's Buyback Yield % too high?
XSpray Pharma AB's current Buyback Yield % is -22.26. Based on the distribution chart, XSpray Pharma AB ranks #502 out of 735 companies in the Biotechnology industry, which is below the industry midpoint. Overall, XSpray Pharma AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does XSpray Pharma AB's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XSpray Pharma AB ranks #502 out of 735 companies for Buyback Yield %. This places XSpray Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on XSpray Pharma AB and its competitors. XSpray Pharma AB's current Buyback Yield % is -22.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XSpray Pharma AB stock overvalued right now?
XSpray Pharma AB (OSTO:XSPRAY) has a current Buyback Yield % of -22.26. The current Buyback Yield % is -22.26. XSpray Pharma AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For XSpray Pharma AB (OSTO:XSPRAY), the current Buyback Yield % is -22.26 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
29GF Score
Get the complete analysis for OSTO:XSPRAY
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:XSPRAY has been successfully added to your 
